Illustration of a heart with interconnected pathways, symbolizing systemic right ventricle and hope for long-term heart health.

Beyond the Trial: How Valsartan Impacts Long-Term Heart Health in Congenital Conditions

Author's portrait.
Soraya Malik in Health & Wellness November 2025 • 5 min read.

"New research reveals the extended effects of valsartan on patients with systemic right ventricle, offering insights into managing congenital heart conditions and improving long-term outcomes."


Congenital heart defects, particularly those resulting in a systemic right ventricle (RV), pose significant long-term challenges. These conditions, often stemming from corrected transposition of the great arteries (TGA), can lead to gradual heart failure and increased morbidity. Managing these complex cases requires a nuanced approach, and researchers are continually exploring the role of medications like valsartan in improving patient outcomes.

Valsartan, an angiotensin II receptor blocker, has been investigated for its potential to improve heart function in patients with systemic RV. Initial studies, such as the VAL-SERVE trial, showed promise in improving ventricular function, especially in symptomatic individuals. However, the long-term effects of valsartan have remained an area of ongoing research.

A recent study published in the International Journal of Cardiology delves deeper into the extended clinical outcomes of valsartan treatment. By following patients over a longer period, researchers aimed to determine whether the early benefits of valsartan translate into sustained improvements in survival and overall heart health. This article will unpack the findings of this study, offering clear insights into who might benefit most from valsartan and what it means for managing congenital heart conditions.

Valsartan and the Systemic Right Ventricle: What the Study Revealed

Illustration of a heart with interconnected pathways, symbolizing systemic right ventricle and hope for long-term heart health.

The study, a follow-up to the VAL-SERVE trial, examined 88 adults with TGA who were initially randomized to receive either valsartan or a placebo for three years. Researchers tracked these patients for an average of 8.3 years after the trial's conclusion, gathering data on their cardiac health, medication use, and survival rates. This long-term perspective allowed for a comprehensive assessment of valsartan's impact beyond the initial treatment period.

The results indicated that while valsartan did not significantly improve overall survival in the entire group, it did show a notable benefit for symptomatic patients. Specifically, valsartan was associated with a decreased risk of clinical events, such as arrhythmia, heart failure, tricuspid valve surgery, and death, in those who were symptomatic at the start of the study. This suggests that valsartan may play a crucial role in managing heart failure symptoms and improving the quality of life for specific patient subgroups.

  • No Overall Survival Benefit: Valsartan did not improve overall survival rates across the entire study group.
  • Reduced Risk for Symptomatic Patients: Symptomatic patients experienced a significant reduction in the risk of adverse clinical events.
  • Consistent Cardiac Drug Use: Cardiac drug use and follow-up were similar between the valsartan and placebo groups.
  • Mortality Causes: Deaths were primarily attributed to heart failure and related complications.
The study also explored the use of other medications, such as ACE inhibitors and beta-blockers, during the follow-up period. The researchers found no significant differences in the use of these drugs between the valsartan and placebo groups, suggesting that the observed benefits in symptomatic patients were likely due to the specific effects of valsartan rather than other medications. Further analysis indicated that valsartan's positive impact was consistent, even when considering the use of other renin-angiotensin-aldosterone system (RAAS) inhibitors.

The Bottom Line: Personalizing Treatment for Congenital Heart Conditions

This research underscores the importance of personalized treatment strategies for individuals with congenital heart conditions. While valsartan may not be a universal solution, it appears to offer significant benefits for symptomatic patients with a systemic RV. By identifying those who are most likely to benefit, clinicians can make more informed decisions about medication use, ultimately improving patient outcomes and quality of life. Further studies are needed to refine these strategies and explore additional interventions that can support long-term heart health in this vulnerable population.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What is the primary focus of this research regarding valsartan?

The primary focus is on the long-term effects of valsartan in patients with a systemic right ventricle (RV), particularly those with congenital heart conditions like corrected transposition of the great arteries (TGA). The research investigates whether the early benefits observed in trials like VAL-SERVE translate into sustained improvements in survival and overall heart health over an extended period of time.

2

How does valsartan impact patients with a systemic right ventricle (RV) differently compared to those without symptoms?

The study showed a significant difference in valsartan's impact based on symptoms. While valsartan did not improve overall survival rates across the entire group, it notably benefited symptomatic patients. These patients experienced a decreased risk of adverse clinical events such as arrhythmia, heart failure, tricuspid valve surgery, and death. This suggests that valsartan is more effective for symptomatic individuals.

3

What were the key findings regarding the use of valsartan in managing patients with congenital heart conditions?

The key findings include: valsartan did not significantly improve overall survival rates across the entire study group; symptomatic patients experienced a significant reduction in the risk of adverse clinical events; cardiac drug use, including ACE inhibitors and beta-blockers, was similar between the valsartan and placebo groups, suggesting the benefits were likely due to valsartan itself. Deaths were primarily attributed to heart failure and related complications.

4

Can valsartan be considered a universal solution for all congenital heart conditions, and what does the study suggest about personalized treatment?

No, valsartan is not a universal solution. The research underscores the importance of personalized treatment strategies. While valsartan did not show overall survival benefits for all patients, it offered significant advantages for symptomatic patients with a systemic RV. This highlights the need for clinicians to identify the patient subgroups most likely to benefit from valsartan to improve outcomes and quality of life, leading to a more tailored approach to medication use.

5

How does this research on valsartan contribute to the ongoing management of congenital heart conditions like TGA?

This research provides valuable insights into the use of valsartan in managing complex congenital heart conditions, especially those involving a systemic RV. It suggests that valsartan can play a crucial role in managing heart failure symptoms and improving the quality of life, especially for symptomatic patients. By understanding who benefits most, clinicians can make more informed decisions, potentially improving patient outcomes. The findings highlight the need for continued research to refine treatment strategies and explore additional interventions that can support long-term heart health in this vulnerable population.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.